<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449486</url>
  </required_header>
  <id_info>
    <org_study_id>5070221</org_study_id>
    <nct_id>NCT02449486</nct_id>
  </id_info>
  <brief_title>Ropivacaine After Sternotomy</brief_title>
  <acronym>NAROSYD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous ropivacaine infusion to sternotomy wound after coronary artery bypass grafting
      (CABG) or heart valve surgery to diminish postoperative pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multiporous catheter will be introduced into sternotomy wound to CABG or heart valve
      surgery patients and continuous ropivacaine infusion 4 ml/h will be started immediately
      after surgery. Ropivacaine infusion will be administered during 48 postoperative hours. All
      patients receive patient controlled analgesia (PCA) oxycodone after extubation in the PACU.
      All patients receive a standardized anesthesia during surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative oxycodone consumption</measure>
    <time_frame>48 postoperative hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain measured with Visual Analog Scale</measure>
    <time_frame>48 postoperative hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion 4 ml/h for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective CABG or heart valve surgery patients

        Exclusion Criteria:

          -  Psychic disorders

          -  Sleep apnea syndrome

          -  Diabetes mellitus (insulin dependent)

          -  Obesity, body mass index (BMI) ≥ 35

          -  Cardiac insufficiency, ejection fraction (EF) ≤ 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi K Lahtinen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kuopio University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pasi K Lahtinen, MD, PhD</last_name>
    <phone>447174871</phone>
    <phone_ext>+358</phone_ext>
    <email>pasi.lahtinen@kuh.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pawel Florkiewicz, MD</last_name>
    <phone>447175049</phone>
    <phone_ext>+358</phone_ext>
    <email>pawel.florkiewicz@kuh.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kuopio University hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>FI70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasi K Lahtinen, MD, PhD</last_name>
      <phone>447174871</phone>
      <phone_ext>+358</phone_ext>
      <email>pasi.lahtinen@kuh.fi</email>
    </contact>
    <contact_backup>
      <last_name>Pawel Florkiewicz, MD</last_name>
      <phone>447175049</phone>
      <phone_ext>+358</phone_ext>
      <email>pawel.florkiewicz@kuh.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Tadeusz Musialowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>August 5, 2015</lastchanged_date>
  <firstreceived_date>May 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Requirement of postoperative pain medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
